Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.
|Videos|November 18, 2013
The Role of Chemotherapy in Prostate Cancer
Author(s)William Kevin Kelly, DO
William Kevin Kelly, DO, discusses the role of chemotherapy in castration-resistant prostate cancer.
Advertisement
William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the role of chemotherapy in castration-resistant prostate cancer (CRPC).
Clinical Pearls
- Chemotherapy has been used to treat CRPC for a long time
- Docetaxel has become a key chemotherapy agent used to treat CRPC for the last decade
- Physicians have tried to use docetaxel with other newer targeted agents, but combining agents with docetaxel has not shown any clinical benefit
Advertisement
Related to this article
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Oncologists discuss LITESPARK-011 findings and the potential role of belzutifan plus lenvatinib in second-line advanced renal cell carcinoma treatment and sequencing.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5